Tγδ大颗粒淋巴细胞白血病(LGLL)识别出症状更重的亚群:一项137例国际队列分析
该研究回顾性分析了1997年至2020年8个转诊中心的137例Tγδ大颗粒淋巴细胞白血病(LGLL)患者,描述其临床与生物学特征,并与129例Tαβ LGLL队列比较。Tγδ组中性粒细胞减少(P=.0161)、贫血(P<.0001)、重度贫血(P=.0065)和血小板减少(P=.0187)更常见,总生存更差(P=.0017);STAT3和STAT5b突变频率无差异。
要点
- Tγδ LGLL患者中性粒细胞减少和贫血常见,分别占54.2%和49.6%。
- 环孢素A在多种治疗中显示出最佳缓解率。
- 与Tαβ LGLL相比,Tγδ LGLL症状更频繁且生存更差。
核心结论
- Tγδ LGLL是T-LGLL的一个亚群,与Tαβ LGLL相比症状更频繁且生存更差。
研究设计与样本
- 回顾性收集1997年至2020年8个转诊中心的137例Tγδ LGLL患者数据,并与已发表的129例Tαβ队列比较。
主要发现
- 中性粒细胞减少占54.2%,贫血占49.6%,重度中性粒细胞减少和重度贫血各约20%。
- 97例和94例分别可进行STAT3和STAT5b突变分析,突变率分别为38.1%和4.2%。
- Tγδ组较Tαβ组更常见中性粒细胞减少(P=.0161)、贫血(P<.0001)、重度贫血(P=.0065)和血小板减少(P=.0187)。
- Vδ2阴性患者症状性疾病频率更高。
- Tγδ组生存较Tαβ组更差(P=.0017)。
关键数值与推荐
- Tγδ组中性粒细胞减少54.2%,贫血49.6%,重度中性粒细胞减少和重度贫血各约20%。
- STAT3突变率38.1%,STAT5b突变率4.2%。
- Tγδ组较Tαβ组中性粒细胞减少P=.0161,贫血P<.0001,重度贫血P=.0065,血小板减少P=.0187。
- Tγδ组较Tαβ组生存更差P=.0017。
- 环孢素A在多种治疗中显示最佳缓解率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαβ LGLL, particularly in terms of frequency of STAT3 and STAT5b mutations. In this study, we characterized the clinical and biological features of 137 patients affected by Tγδ LGLL; data were retrospectively collected from 1997 to 2020 at 8 referral centers. Neutropenia and anemia were the most relevant clinical features, being present in 54.2% and 49.6% of cases, respectively, including severe neutropenia and anemia in ∼20% of cases each. Among the various treatments, cyclosporine A was shown to provide the best response rates. DNA samples of 97 and 94 cases were available for STAT3 and STAT5b mutation analysis, with 38.1% and 4.2% of cases being mutated, respectively. Clinical and biological features of our series of Tγδ cases were also compared with a recently published Tαβ cohort including 129 cases. Though no differences in STAT3 and STAT5b mutational frequency were found, Tγδ cases more frequently presented with neutropenia (P = .0161), anemia (P < .0001), severe anemia (P = .0065), and thrombocytopenia (P = .0187). Moreover, Vδ2- cases displayed higher frequency of symptomatic disease. Overall, Tγδ cases displayed reduced survival with respect to Tαβ cases (P = .0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tγδ LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared with Tαβ LGLL.
引用
- Barilà G, Grassi A, Cheon H, et al. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. Blood. 2023. PMID: 36096473. doi:10.1182/blood.2021013489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。